Drugs / FIGOPITANT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02209714 | Nov 1999 → Feb 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02203487 | Nov 1999 → Jun 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02199899 | Mar → Jul 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIGOPITANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104927 ↗ |
| Known as | Biif 1149 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104927 ↗ |
| Known as | BIIF 1149 BS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02209714 ↗ |
| Known as | BIIF 1149 CL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104927 ↗ |
| Action | Inhibit | “Neurokinin 1 receptor antagonist” CHEMBL2104927 ↗ |
| Modality | Small molecule | — CHEMBL2104927 ↗ |
| Route | Oral | “After Oral Administration of BIIF 1149 BS” NCT02199899 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL2104927 ↗ |